Bioscrip, Inc. (BIOS) rated Buy with price target $6 by Broadpoint Capital
Bioscrip (BIOS) rated Buy
with price target $6 by Broadpoint Capital.
BioScrip, Inc. is a specialty pharmaceutical healthcare organization that partners with patients, physicians, healthcare payors and pharmaceutical manufacturers to provide access to medications and management solutions. The Company has two operating segments: specialty pharmaceutical services (Specialty Services) and pharmacy benefit management (PBM) services. The Company's Specialty Services include the support, dispensing and distribution, patient care management, data reporting, as well as a range of other therapy management services for chronic health conditions. These medications include orals, injectables and infusibles used to treat patients living with chronic health conditions and are provided directly to patients and physicians. Its PBM services include pharmacy network management, claims processing and benefit design, clinical services, drug utilization review, discount prescription card programs and mail order pharmacy fulfillment.
, Inc. is an investment banking and capital markets firm that provides corporate and public finance services and trading of corporate, government, and municipal securities for institutions. The company has three divisions: Municipal Capital Markets division, which underwrites and trades municipal securities in new issue and secondary markets; Taxable Fixed Income division, which is a dealer focusing on fixed income securities with limited liquidity; and Equity Capital Markets division, which is a sector-focused investment banking group providing research, trading, raising of capital and advisory services for institutional and corporate clients. Broadpoint Capital
, formerly known as First Albany Corporation, was founded in 1953 and is based in New York, New York. The company operates as a subsidiary of First Albany Companies Inc.